These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32681778)

  • 1. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
    Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
    Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
    Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
    Drug Metab Pers Ther; 2020 Jun; ():. PubMed ID: 32609649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.
    Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR
    Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
    Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
    Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.
    Goswami S; Yee SW; Stocker S; Mosley JD; Kubo M; Castro R; Mefford JA; Wen C; Liang X; Witte J; Brett C; Maeda S; Simpson MD; Hedderson MM; Davis RL; Roden DM; Giacomini KM; Savic RM
    Clin Pharmacol Ther; 2014 Sep; 96(3):370-9. PubMed ID: 24853734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
    Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
    Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
    Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of
    Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes.
    Gonzalez-Covarrubias V; Sánchez-Ibarra H; Lozano-Gonzalez K; Villicaña S; Texis T; Rodríguez-Dorantes M; Cortés-Ramírez S; Lavalle-Gonzalez F; Soberón X; Barrera-Saldaña H
    Pharmacology; 2021; 106(11-12):588-596. PubMed ID: 34265779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
    Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
    Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
    Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M
    Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
    Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
    PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
    Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
    Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of the Gly972Arg, SNP43 and Prol2Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México].
    García-Escalante MG; Suárez-Solís VM; López-Avila MT; Pinto-Escalante Ddel C; Laviada-Molina H
    Invest Clin; 2009 Mar; 50(1):65-76. PubMed ID: 19418728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
    Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
    JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
    Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
    Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.